Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2011 April;52(2) > The Journal of Cardiovascular Surgery 2011 April;52(2):231-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  DRUG-ELUTING TECHNOLOGIES: WHERE ARE WE 

The Journal of Cardiovascular Surgery 2011 April;52(2):231-4

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents below the knee

Bosiers M. 1, Deloose K. 1, Callaert J. 1, Keirse K. 2, Verbist J. 2, Peeters P. 2

1 Department of Vascular Surgery, A.Z. Sint-Blasius, Dendermonde, Belgium; 2 Department of Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium


PDF


The fear that early thrombosis and late luminal loss due to intimal hyperplasia formation potentially leads to insufficient long-term patency rates can explain the reluctance on implanting stents in small diameter below-the-knee (BTK) arteries. Drug-eluting stent (DES) technology was developed to prevent early thrombosis and late luminal loss to potentially improve long-term patency rates. Currently, the first level 1 evidence from prospective, randomized, controlled DESTINY and ACHILLES studies indicate that the implantation of DES in short lesion lenghts in the infrapopliteal vasculature leads to favorable outcomes with high primary patency rates. This makes that primary DES placement can be recommended as treatment strategy in short BTK-lesions.

top of page